The CD123 Talacotuzumab Biosimilar MAB (HDBS0003) is a groundbreaking monoclonal antibody targeting CD123, a protein overexpressed in certain leukemic cells, with potential applications in cancer treatment. Talacotuzumab, a biosimilar of a well-known therapeutic antibody, has been engineered to specifically bind to CD123, inhibiting its function and potentially disrupting the growth and survival of cancer cells.This antibody, developed using advanced biotechnological methods, has shown high specificity and potency in preclinical studies, making it a promising candidate for targeted cancer therapy. By targeting CD123, which is highly expressed in leukemia and other hematologic malignancies, talacotuzumab offers a novel approach to treatment that may enhance the efficacy and reduce the side effects of traditional chemotherapy.
The Anti-CD123 Talacotuzumab Biosimilar MAB (HDBS0003) represents a new weapon in the fight against cancer, with the potential to revolutionize treatment strategies and improve outcomes for patients with CD123-expressing cancers. Its development opens up exciting possibilities for personalized medicine and precision oncology, offering hope for those facing the challenges of this devastating disease.
Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.
Storage & Shipping:
Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing).Lyophilized antibodies are shipped at ambient temperature.
Common Name:
CSL-362-AML, CSL362, JNJ-56022473
Buffer:
Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.
Format:
Powder
Applications
ELISA, Flow Cyt
Antibody Isotype:
IgG1
Guarantee:
12 months from date of dispatch
Background:
Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
